NEUROCRINE BIOSCIENCES INC Research and Development Asset Acquired Other than Through Business Combination, Written-off
NEUROCRINE BIOSCIENCES INC (NBIX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $1.50M.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $21.20M, a 21100.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $17.00M, a 466.67% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $300.00K, a 70.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for fiscal 2025 was $17.40M, a 39.20% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for fiscal 2024 was $12.50M, a 91.31% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for fiscal 2023 was $143.90M.
- NEUROCRINE BIOSCIENCES INC research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-07-31 | $22.70M 10-Q · filed 2026-07-31 | $39.70M derived: sum of 3 quarters · filed 2026-07-31 | $40.00M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $21.20M 10-Q · filed 2026-05-05 | $38.20M derived: sum of 2 quarters · filed 2026-05-05 | $38.50M derived: sum of 3 quarters · filed 2026-05-05 | $38.50M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $17.30M derived: sum of 2 quarters · filed 2026-02-11 | $17.30M derived: sum of 3 quarters · filed 2026-07-31 | $17.40M 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $300.00K 10-Q · filed 2025-10-28 | $300.00K derived: sum of 2 quarters · filed 2026-07-31 | $400.00K 10-Q · filed 2025-10-28 | $3.40M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-31 | $100.00K 10-Q · filed 2026-07-31 | $3.10M derived: sum of 3 quarters · filed 2026-07-31 | $4.10M derived: sum of 4 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-05 | $3.10M derived: sum of 2 quarters · filed 2026-05-05 | $4.10M derived: sum of 3 quarters · filed 2026-05-05 | $6.60M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $4.00M derived: sum of 2 quarters · filed 2026-02-11 | $6.50M derived: sum of 3 quarters · filed 2026-02-11 | $12.50M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $1.00M 10-Q · filed 2025-10-28 | $3.50M derived: sum of 2 quarters · filed 2025-10-28 | $9.50M 10-Q · filed 2025-10-28 | $9.50M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $2.50M 10-Q · filed 2025-07-30 | $8.50M 10-Q · filed 2025-07-30 | $8.50M derived: sum of 3 quarters · filed 2026-02-11 | $8.50M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $6.00M 10-Q · filed 2025-05-05 | $6.00M derived: sum of 2 quarters · filed 2026-02-11 | $6.00M derived: sum of 3 quarters · filed 2026-02-11 | $6.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $143.90M 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $143.90M 10-Q · filed 2024-10-30 | $143.90M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $143.90M 10-Q · filed 2024-08-01 | $143.90M derived: sum of 3 quarters · filed 2025-02-10 | $143.90M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-03-31 | $143.90M 10-Q · filed 2024-05-01 | $143.90M derived: sum of 2 quarters · filed 2025-02-10 | $143.90M derived: sum of 3 quarters · filed 2025-02-10 | $143.90M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-10 | $0.00 derived: sum of 3 quarters · filed 2025-02-10 | $0.00 10-K · filed 2025-02-10 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | $100.30M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | $100.30M derived: sum of 3 quarters · filed 2024-02-09 | $100.30M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $100.30M derived: sum of 2 quarters · filed 2024-02-09 | $100.30M derived: sum of 3 quarters · filed 2024-02-09 | $105.30M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $100.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $100.30M derived: sum of 2 quarters · filed 2024-02-09 | $105.30M derived: sum of 3 quarters · filed 2024-02-09 | $105.30M 10-K · filed 2024-02-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-01 | $5.00M derived: sum of 2 quarters · filed 2022-11-01 | $5.00M 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | $5.00M 10-Q · filed 2022-08-04 | $5.00M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $118.50M derived: sum of 2 quarters · filed 2023-02-09 | $164.50M derived: sum of 3 quarters · filed 2023-02-09 | $164.50M 10-K · filed 2023-02-09 | ||
| 2020-09-30 | $118.50M 10-Q · filed 2021-11-01 | $164.50M derived: sum of 2 quarters · filed 2021-11-01 | $164.50M 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | $46.00M 10-Q · filed 2021-08-03 | $46.00M 10-Q · filed 2021-08-03 | ||||
| 2019-12-31 | $36.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $36.20M derived: sum of 2 quarters · filed 2022-02-11 | $41.20M derived: sum of 3 quarters · filed 2022-02-11 | $154.30M 10-K · filed 2022-02-11 | $154.27M 10-K · filed 2020-02-07 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $5.00M derived: sum of 2 quarters · filed 2020-11-09 | $118.10M 10-Q · filed 2020-11-09 | $118.08M 10-Q · filed 2019-11-04 | ||
| 2019-06-30 | $5.00M 10-Q · filed 2020-08-03 | $118.10M 10-Q · filed 2020-08-03 | ||||
| 2019-03-31 | $113.10M 10-Q · filed 2020-05-06 | |||||
| 2018-12-31 | $4.80M 10-K · filed 2021-02-05 | $4.75M 10-K · filed 2020-02-07 | ||||
| 2017-12-31 | $30.00M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |